Healthcare - Biotechnology - NASDAQ - US
$ 4.76
-5.18 %
$ 326 M
Market Cap
-1.25
P/E
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.[ Read More ]
The intrinsic value of one AMLX stock under the base case scenario is HIDDEN Compared to the current market price of 4.76 USD, Amylyx Pharmaceuticals, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart AMLX
FINANCIALS
381 M
REVENUE
38.8 M
OPERATING INCOME
49.3 M
NET INCOME
11.9 M
OPERATING CASH FLOW
92.1 M
INVESTING CASH FLOW
3.54 M
FINANCING CASH FLOW
416 K
REVENUE
-75.7 M
OPERATING INCOME
-72.7 M
NET INCOME
-41.6 M
OPERATING CASH FLOW
38.8 M
INVESTING CASH FLOW
80 K
FINANCING CASH FLOW
Balance Sheet Decomposition
Amylyx Pharmaceuticals, Inc.
| Current Assets | 465 M |
| Cash & Short-Term Investments | 371 M |
| Receivables | 40 M |
| Other Current Assets | 53.3 M |
| Non-Current Assets | 52.8 M |
| Long-Term Investments | 0 |
| PP&E | 6.41 M |
| Other Non-Current Assets | 46.4 M |
| Current Liabilities | 82 M |
| Accounts Payable | 22.1 M |
| Short-Term Debt | 4.51 M |
| Other Current Liabilities | 55.5 M |
| Non-Current Liabilities | 1.98 M |
| Long-Term Debt | 1.98 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Amylyx Pharmaceuticals, Inc.
| Revenue | 381 M |
| Cost Of Revenue | 25.4 M |
| Gross Profit | 355 M |
| Operating Expenses | 317 M |
| Operating Income | 38.8 M |
| Other Expenses | -10.5 M |
| Net Income | 49.3 M |
RATIOS
93.32%
GROSS MARGIN
10.19%
OPERATING MARGIN
12.94%
NET MARGIN
11.37%
ROE
9.52%
ROA
8.08%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Amylyx Pharmaceuticals, Inc.
| Net Income | 49.3 M |
| Depreciation & Amortization | 1.09 M |
| Capital Expenditures | -1.24 M |
| Stock-Based Compensation | 37.2 M |
| Change in Working Capital | -65.7 M |
| Others | -91.5 M |
| Free Cash Flow | 10.7 M |
Wall Street Analysts Price Targets
Amylyx Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for AMLX of $5.14 , with forecasts ranging from a low of $3 to a high of $10 .
AMLX Lowest Price Target
Wall Street Target
3 USD
-36.97%
AMLX Average Price Target
Wall Street Target
5.14 USD
8.04%
AMLX Highest Price Target
Wall Street Target
10 USD
110.08%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0.42 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Amylyx Pharmaceuticals, Inc.
Sold
0-3 MONTHS
183 K USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
290 K USD 4
9-12 MONTHS
281 K USD 4
Bought
428 K USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
9.44 K USD 1
6-9 MONTHS
59.9 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 month ago
Sep 30, 2024
|
Sell 59.4 K USD
|
Klee Justin B.
Co-Chief Executive Officer |
- 18589
|
3.197 USD |
|
1 month ago
Sep 30, 2024
|
Sell 59.4 K USD
|
Cohen Joshua B
Co-Chief Executive Officer |
- 18589
|
3.1962 USD |
|
1 month ago
Sep 30, 2024
|
Sell 36.6 K USD
|
Bedrosian Camille L
Chief Medical Officer |
- 11442
|
3.1952 USD |
|
1 month ago
Sep 30, 2024
|
Sell 27.8 K USD
|
Mazzariello Gina
Chief Legal Officer |
- 8709
|
3.1967 USD |
|
2 months ago
Sep 12, 2024
|
Bought 101 K USD
|
FRATES JAMES M
Chief Financial Officer |
+ 40000
|
2.5342 USD |
|
2 months ago
Sep 05, 2024
|
Bought 107 K USD
|
Firestone Karen
Director |
+ 50000
|
2.1318 USD |
|
2 months ago
Sep 03, 2024
|
Bought 220 K USD
|
MILNE GEORGE M JR
Director |
+ 100000
|
2.198 USD |
|
6 months ago
May 15, 2024
|
Bought 4.25 K USD
|
Quimi Daphne
Director |
+ 2250
|
1.8899 USD |
|
6 months ago
May 14, 2024
|
Bought 5.18 K USD
|
Quimi Daphne
Director |
+ 2750
|
1.885 USD |
|
6 months ago
May 15, 2024
|
Sell 19.7 K USD
|
Mazzariello Gina
Chief Legal Officer |
- 10455
|
1.8799 USD |
|
8 months ago
Mar 05, 2024
|
Sell 77.4 K USD
|
Cohen Joshua B
Co-Chief Executive Officer |
- 4135
|
18.7279 USD |
|
8 months ago
Mar 05, 2024
|
Sell 77.4 K USD
|
Klee Justin B.
Co-Chief Executive Officer |
- 4135
|
18.7279 USD |
|
8 months ago
Mar 05, 2024
|
Sell 33.6 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 1792
|
18.7279 USD |
|
8 months ago
Mar 05, 2024
|
Sell 28.8 K USD
|
Mazzariello Gina
Chief Legal Officer |
- 1540
|
18.7279 USD |
|
8 months ago
Feb 23, 2024
|
Sell 53.2 K USD
|
Mazzariello Gina
Chief Legal Officer |
- 2838
|
18.7564 USD |
|
10 months ago
Jan 09, 2024
|
Sell 95.4 K USD
|
Klee Justin B.
Co-Chief Executive Officer |
- 5841
|
16.3281 USD |
|
10 months ago
Jan 09, 2024
|
Sell 44.3 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 2716
|
16.3281 USD |
|
10 months ago
Jan 09, 2024
|
Sell 95.4 K USD
|
Cohen Joshua B
Co-Chief Executive Officer |
- 5841
|
16.3281 USD |
|
10 months ago
Jan 09, 2024
|
Sell 45.9 K USD
|
Yeramian Patrick D
Chief Medical Officer |
- 2812
|
16.3281 USD |
|
11 months ago
Dec 15, 2023
|
Bought 59.9 K USD
|
Firestone Karen
Director |
+ 4000
|
14.97 USD |
|
1 year ago
Aug 15, 2023
|
Sell 129 K USD
|
Mazzariello Gina
Chief Legal Officer |
- 6164
|
20.8771 USD |
|
1 year ago
May 16, 2023
|
Sell 862 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 32000
|
26.9266 USD |
|
1 year ago
May 16, 2023
|
Sell 13.8 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 500
|
27.6 USD |
|
1 year ago
May 15, 2023
|
Sell 347 K USD
|
Yeramian Patrick D
Chief Medical Officer |
- 11965
|
29.0312 USD |
|
1 year ago
Apr 17, 2023
|
Sell 1.5 M USD
|
Yeramian Patrick D
Chief Medical Officer |
- 49279
|
30.5335 USD |
|
1 year ago
Apr 17, 2023
|
Sell 9.28 K USD
|
Yeramian Patrick D
Chief Medical Officer |
- 300
|
30.94 USD |
|
1 year ago
Mar 29, 2023
|
Sell 885 K USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 29048
|
30.45 USD |
|
1 year ago
Mar 27, 2023
|
Sell 997 K USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 32964
|
30.25 USD |
|
1 year ago
Mar 27, 2023
|
Sell 862 K USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 28000
|
30.8 USD |
|
1 year ago
Mar 28, 2023
|
Sell 3.04 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 100000
|
30.37 USD |
|
1 year ago
Mar 16, 2023
|
Sell 981 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 30796
|
31.8593 USD |
|
1 year ago
Mar 16, 2023
|
Sell 55.3 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 1704
|
32.4649 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.66 M USD
|
Yeramian Patrick D
Chief Medical Officer |
- 52211
|
31.8485 USD |
|
1 year ago
Mar 16, 2023
|
Sell 78.4 K USD
|
Yeramian Patrick D
Chief Medical Officer |
- 2416
|
32.4331 USD |
|
1 year ago
Mar 21, 2023
|
Sell 1.1 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 34641
|
31.69 USD |
|
1 year ago
Mar 21, 2023
|
Sell 927 K USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 28807
|
32.17 USD |
|
1 year ago
Mar 16, 2023
|
Sell 3.07 M USD
|
Klee Justin B.
Co-Chief Executive Officer |
- 96555
|
31.8405 USD |
|
1 year ago
Mar 16, 2023
|
Sell 112 K USD
|
Klee Justin B.
Co-Chief Executive Officer |
- 3445
|
32.4751 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.05 M USD
|
MILNE GEORGE M JR
Director |
- 33084
|
31.8553 USD |
|
1 year ago
Mar 16, 2023
|
Sell 62.2 K USD
|
MILNE GEORGE M JR
Director |
- 1916
|
32.4487 USD |
|
1 year ago
Mar 16, 2023
|
Sell 1.66 M USD
|
Yeramian Patrick D
Chief Medical Officer |
- 52211
|
31.8485 USD |
|
1 year ago
Mar 16, 2023
|
Sell 78.4 K USD
|
Yeramian Patrick D
Chief Medical Officer |
- 2416
|
32.4331 USD |
|
1 year ago
Mar 16, 2023
|
Bought 32 K USD
|
Firestone Karen
Director |
+ 1000
|
31.99 USD |
|
1 year ago
Mar 16, 2023
|
Sell 3.06 M USD
|
Cohen Joshua B
Co-Chief Executive Officer |
- 96076
|
31.8396 USD |
|
1 year ago
Mar 16, 2023
|
Sell 127 K USD
|
Cohen Joshua B
Co-Chief Executive Officer |
- 3924
|
32.4451 USD |
|
1 year ago
Mar 16, 2023
|
Sell 981 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 30796
|
31.8593 USD |
|
1 year ago
Mar 16, 2023
|
Sell 55.3 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 1704
|
32.4649 USD |
|
1 year ago
Mar 16, 2023
|
Sell 297 K USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 9122
|
32.55 USD |
|
1 year ago
Mar 14, 2023
|
Sell 2.44 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 70714
|
34.54 USD |
|
1 year ago
Mar 15, 2023
|
Sell 3.61 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 108934
|
33.12 USD |
|
1 year ago
Mar 15, 2023
|
Sell 1.38 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 41066
|
33.68 USD |
|
1 year ago
Mar 02, 2023
|
Sell 1.69 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 50000
|
33.75 USD |
|
1 year ago
Feb 24, 2023
|
Sell 124 K USD
|
Mazzariello Gina
Chief Legal Officer |
- 3586
|
34.4874 USD |
|
1 year ago
Feb 22, 2023
|
Sell 1.66 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 47888
|
34.7 USD |
|
1 year ago
Feb 22, 2023
|
Sell 74.6 K USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 2112
|
35.34 USD |
|
1 year ago
Feb 22, 2023
|
Sell 1.43 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 39916
|
35.91 USD |
|
1 year ago
Feb 22, 2023
|
Sell 366 K USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 10084
|
36.34 USD |
|
1 year ago
Feb 23, 2023
|
Sell 1.74 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 48889
|
35.55 USD |
|
1 year ago
Feb 23, 2023
|
Sell 40.3 K USD
|
Morningside Venture Investments Ltd
10 percent owner |
- 1111
|
36.24 USD |
|
1 year ago
Jan 06, 2023
|
Sell 50.7 K USD
|
Yeramian Patrick D
Chief Medical Officer |
- 1405
|
36.0789 USD |
|
1 year ago
Jan 06, 2023
|
Sell 23.1 K USD
|
Yeramian Patrick D
Chief Medical Officer |
- 629
|
36.7888 USD |
|
1 year ago
Jan 06, 2023
|
Sell 149 K USD
|
Cohen Joshua B
Co-Chief Executive Officer |
- 4122
|
36.0789 USD |
|
1 year ago
Jan 06, 2023
|
Sell 67.9 K USD
|
Cohen Joshua B
Co-Chief Executive Officer |
- 1846
|
36.7888 USD |
|
1 year ago
Jan 06, 2023
|
Sell 66.2 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 1836
|
36.0789 USD |
|
1 year ago
Jan 06, 2023
|
Sell 30.2 K USD
|
FRATES JAMES M
Chief Financial Officer |
- 822
|
36.7888 USD |
|
1 year ago
Jan 06, 2023
|
Sell 59.9 K USD
|
Olinger Margaret
Chief Commercial Officer |
- 1660
|
36.0789 USD |
|
1 year ago
Jan 06, 2023
|
Sell 27.3 K USD
|
Olinger Margaret
Chief Commercial Officer |
- 743
|
36.7888 USD |
|
1 year ago
Jan 06, 2023
|
Sell 149 K USD
|
Klee Justin B.
Co-Chief Executive Officer |
- 4122
|
36.0789 USD |
|
1 year ago
Jan 06, 2023
|
Sell 67.9 K USD
|
Klee Justin B.
Co-Chief Executive Officer |
- 1846
|
36.7888 USD |
|
2 years ago
Jul 06, 2022
|
Sell 358 K USD
|
ALS Invest 1 B.V.
director: |
- 18312
|
19.54 USD |
|
2 years ago
Jan 11, 2022
|
Bought 5 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
+ 263158
|
19 USD |
|
2 years ago
Jan 11, 2022
|
Bought 5 M USD
|
Morningside Venture Investments Ltd
10 percent owner |
+ 263158
|
19 USD |
|
2 years ago
Jan 11, 2022
|
Bought 43.7 M USD
|
VIKING GLOBAL INVESTORS LP
|
+ 2300000
|
19 USD |
|
2 years ago
Jan 06, 2022
|
Bought 75 K USD
|
FONTEYNE PAUL R.
Director |
+ 3947
|
19 USD |
|
2 years ago
Jan 06, 2022
|
Bought 125 K USD
|
Cheng Isaac
Director |
+ 6578
|
19 USD |
|
2 years ago
Jan 06, 2022
|
Bought 500 K USD
|
MILNE GEORGE M JR
Director |
+ 26315
|
19 USD |
|
2 years ago
Jan 06, 2022
|
Bought 130 K USD
|
Olinger Margaret
Chief Commercial Officer |
+ 6842
|
19 USD |
7. News
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Chief Executive Officer Conference Call Participants Charlie Yang - Bank of America Merrill Lynch Michael DiFiore - Evercore ISI Graig Suvannavejh - Mizuho Securities USA Basma Radwan - Leerink Partners Ananda Ghosh - H.C. Wainwright & Co. Joel Beatty - Robert W.
seekingalpha.com
- 1 week ago
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
fool.com
- 4 weeks ago
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024.
businesswire.com
- 1 month ago
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO's commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO's prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
prnewswire.com
- 1 month ago
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
globenewswire.com
- 2 months ago
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in New York City: Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5, 2024, at 1:50pm ET Baird 2024 Global Healthcare Conference: Fireside chat on Tuesday, September 10, 2024, at 3:45pm ET H.C. Wainwright 26th Annu.
businesswire.com
- 2 months ago
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2024 Earnings Call Transcript August 8, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Joshua Cohen - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Conference Call Participants Charlie Yang - Bank of America Operator Good morning. My name is Camille, and I will be your conference operator for today.
seekingalpha.com
- 3 months ago
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK , July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO's commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO's prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO's prescription data; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
prnewswire.com
- 3 months ago
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals Inc AMLX acquired avexitide from Eiger BioPharmaceuticals Inc EIGRQ for $35.1 million.
benzinga.com
- 4 months ago
Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Avexitide Acquisition Conference Call July 10, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Joshua Cohen - Co-Chief Executive Officer Camille Bedrosian - Chief Medical Officer James Frates - Chief Financial Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Michael DiFiore - Evercore ISI Graig Suvannavejh - Mizuho Securities Charlie Yang - Bank of America Merrill Lynch Joel Beatty - Robert W. Baird & Company Ananda Ghosh - H.C.
seekingalpha.com
- 4 months ago
This cheap biotech offers investors a play on ALS if trial data continues to impress
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
marketwatch.com
- 4 months ago
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025.
seekingalpha.com
- 4 months ago
8. Profile Summary
Amylyx Pharmaceuticals, Inc. AMLX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 326 M
Dividend Yield
0.00%
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Contact
43 Thorndike Street, Cambridge, MA, 02141
https://amylyx.com
IPO Date
Jan. 7, 2022
Employees
384
Officers
Ms. Lindsey Allen
Head of Investor Relations & Communications
Mr. Keith White
Head of Global Market Access
Ms. Shauna Horvath
Head of Global Marketing
Mr. Joshua B. Cohen
Co-Founder, Co-Chief Executive Officer & Director
Mr. Justin B. Klee
Co-Founder, Co-Chief Executive Officer & Director
Mr. James M. Frates M.B.A.
Chief Financial Officer
Dr. Camille L. Bedrosian M.D.
Chief Medical Officer
Mr. Tom Holmes
Chief Technical Operations Officer
Ms. Linda A. Arsenault
Chief Human Resources Officer
Mr. Chris Aiello
Head of Canada & GM